Vertex Pharma (VRTX) Tops Q1 EPS by 68c; reiterates guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Vertex (VRTX) PT Raised to $424 at RBC Capital
May 7, 2024 6:21 AM EDTRBC Capital analyst Brian Abrahams raised the price target on Vertex (NASDAQ: VRTX) to $424.00 (from $417.00) while maintaining a Sector Perform rating.
The analyst comments "A solid 1Q optically, with WW CF sales exceeding expectations, though this was driven mainly by ex-U.S.... More
Vertex (VRTX) PT Lowered to $-- at Stifel
May 7, 2024 6:13 AM EDTStifel analyst Paul Matteis lowered the price target on Vertex (NASDAQ: VRTX) to $-- (from $430.00) while maintaining a Hold rating.
The analyst comments "We remain Hold rated on VRTX. The CF franchise posted a beat (helped by inventory) while VRTX reiterated their... More
